Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes

J Immunol. 2003 Nov 1;171(9):4504-11. doi: 10.4049/jimmunol.171.9.4504.

Abstract

Thymic-derived dysregulated tolerance has been suggested to occur in type 1 diabetes via impaired generation of CD4(+)CD25(+) T regulatory cells, leading to autoimmune beta cell destruction. In this study, we demonstrate that Notch3 expression is a characteristic feature of CD4(+)CD25(+) cells. Furthermore, streptozotocin-induced autoimmune diabetes fails to develop in transgenic mice carrying the constitutively active intracellular domain of Notch3 in thymocytes and T cells. The failure to develop the disease is associated with an increase of CD4(+)CD25(+) T regulatory cells, accumulating in lymphoid organs, in pancreas infiltrates and paralleled by increased expression of IL-4 and IL-10. Accordingly, CD4(+) T cells from Notch3-transgenic mice inhibit the development of hyperglycemia and insulitis when injected into streptozotocin-treated wild-type mice and display in vitro suppressive activity. These observations, therefore, suggest that Notch3-mediated events regulate the expansion and function of T regulatory cells, leading to protection from experimental autoimmune diabetes and identify the Notch pathway as a potential target for therapeutic intervention in type 1 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • CD4-Positive T-Lymphocytes / pathology
  • Cell Differentiation / genetics
  • Cell Differentiation / immunology
  • Cell Movement / genetics
  • Cell Movement / immunology
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / immunology
  • Diabetes Mellitus, Experimental / prevention & control*
  • Diabetes Mellitus, Type 1 / genetics
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Drug Administration Schedule
  • Gene Expression Regulation / immunology*
  • Injections, Intraperitoneal
  • Interleukin-10 / biosynthesis
  • Interleukin-10 / genetics
  • Interleukin-4 / biosynthesis
  • Interleukin-4 / genetics
  • Islets of Langerhans / immunology
  • Islets of Langerhans / pathology
  • Lymphoid Tissue / immunology
  • Lymphoid Tissue / metabolism
  • Lymphoid Tissue / pathology
  • Male
  • Mice
  • Mice, Transgenic
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins / metabolism*
  • RNA, Messenger / biosynthesis
  • Receptor, Notch3
  • Receptor, Notch4
  • Receptors, Cell Surface*
  • Receptors, Interleukin-2 / biosynthesis
  • Receptors, Notch
  • Streptozocin / administration & dosage
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocyte Subsets / pathology
  • Up-Regulation / genetics
  • Up-Regulation / immunology*

Substances

  • Notch3 protein, mouse
  • Proto-Oncogene Proteins
  • RNA, Messenger
  • Receptor, Notch3
  • Receptor, Notch4
  • Receptors, Cell Surface
  • Receptors, Interleukin-2
  • Receptors, Notch
  • Interleukin-10
  • Notch4 protein, mouse
  • Interleukin-4
  • Streptozocin